

International Workshop on Viral Biomarkers

Save the date

We invite you to join us for the “International Workshop on Viral Biomarkers” organized by Pr Zoulim in the framework of the **RHU CirB-RNA** funded by **ANR** (Agence Nationale de Recherche).

This event will take place on **September 7, 2023 in Lyon** at the “Hangar du Premier Film” of the **Institut Lumière**.



Free but Mandatory Registration before September 1st, 2023
To register, please send an email to: CirB-RNA2023@inserm.fr

Program

9:30 am – 9:45 am	Welcome Fabien Zoulim, Massimo Levrero, Marantha Heil
9:45 am – 10:15 am	Opening lecture: Why do we need novel biomarkers for the clinical development of HBV cure therapies? Anna Lok (USA) – 30 min (presentation and discussion)
10:15 am	Molecular virology and Biomarkers <u>Chairs:</u> Christian Bréchet (USA), Walter Koch (USA)
10:15 am – 10:40 am	The molecular biology of HBV RNAs: insights on new biomarkers Massimo Levrero (Lyon, France) – 25 min (presentation and discussion)
10:40 am – 11:05 am	New insight on HBV particle trafficking Eberhard Hildt (Langen, Germany) - 25 min (presentation and discussion)
11:05 am – 11:20 am	Characterization of circulating HBV RNAs in hepatocyte cell lines Alexia Paturel (Lyon, France) - 15 min (presentation and discussion)
11:20 am – 11:35 am	Characterization of circulating HBV RNAs in CHB patients and mechanism of cellular export Doohyun Kim (Lyon, France) - 15 min (presentation and discussion)
11:35 am – 11:50 am Coffee break (15 min)	

11:50 am	Assay development <u>Chairs:</u> Gilles Wandeler (Switzerland), Barbara Testoni (France)
11:50 am – 12:15 pm	From discovery of biomarkers to assay development Walter Koch (USA) – 25 min (presentation and discussion)
12:15 pm – 12:40 pm	Development of assays for the quantification of circulating HBV RNA Marintha Heil (Roche, USA) - 25 min (presentation and discussion)
12:40 pm – 1:45 pm Lunch Break (65 min)	
Assay development (continued) 1:45 pm – 2:00 pm	Validation of the investigational assay in clinical cohorts Caroline Scholtès (Lyon, France) - 15 min (presentation and discussion)
2:00 pm – 2:15 pm	Novel assays for the quantification of HBV RNA species Aaron Hamilton (Roche, USA) - 15 min (presentation and discussion)
2:15 pm	Clinical utility of novel HBV biomarkers <u>Chairs:</u> Anna Lok (USA), Antonio Craxi (Italy)
2:15 pm – 2:40 pm	Prediction of outcome after cessation of nucleos(t)ide analog therapy Sabela Lens (Barcelona, Spain) - 25 min (presentation and discussion)
2:40 pm – 3:05 pm	Investigation of viral biomarkers in clinical trials of novel antiviral strategies Fabien Zoulim (Lyon, France) - 25 min (presentation and discussion)
3:05 pm – 3:20 pm Coffee break (15 min)	
Clinical utility of novel HBV biomarkers (continued) 3:20 pm – 3:40 pm	Are serum HBV RNAs and HBcrAg non-invasive markers of intrahepatic cccDNA? Barbara Testoni (Lyon, France) - 20 min (presentation and discussion)
3:40 pm – 4:00 pm	Serum HBV RNAs and HBcrAg in HIV-HBV co-infected patients with HBV functional cure Lorin Bègré (Bern, Switzerland) - 20 min (presentation and discussion)
4:00 pm – 4:20 pm	Serum HBV RNAs and HBcrAg in HBV-HDV co-infected patients Pietro Lampertico (Milan, Italy) - 20 min (presentation and discussion)
4:20 pm – 4:45 pm	Closing lecture: The role of new viral biomarkers to assist the clinical development of HBV cure strategies. The industry perspective. Rob Elston (GSK, UK) - 25 min (presentation and discussion)
4:45 pm – 5:00 pm	Farewell Fabien Zoulim, Massimo Levrero, Marintha Heil